Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEAPOD: Apremilast in children with active juvenile psoriatic arthritis
2023-503435-17-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in juvenile psoriatic arthritis (JPsA) comparing Apremilast with Placebo (2 arms). Primary endpoint: ACR Pedi 30 response. Planned start Mar 2021; status: authorised.
02
Drugs
apremilast
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on 2023-503435-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503435-17-00.